|Bid||1.9200 x 1100|
|Ask||1.9300 x 1000|
|Day's Range||1.8800 - 2.1000|
|52 Week Range||1.2500 - 4.3500|
|Beta (3Y Monthly)||2.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.25|
Nymox Pharmaceutical Corporation (NYMX) today announced that it has held its pre-New Drug Application (NDA) Chemistry Manufacturing and Controls (CMC) meeting with the US Food and Drug Administration (FDA) regarding its lead product candidate Fexapotide Triflutate, a novel prostate injectable developed for the treatment of enlarged prostate (Benign Prostatic Hyperplasia, BPH). The purpose of the April 15 meeting was to discuss the CMC data package for Fexapotide, an important regulatory requirement prior to the NDA submission. Nymox is pleased to report that it considers the meeting was constructive and positive.
HASBROUCK HEIGHTS, N.J., March 21, 2019 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) Nymox will hold a teleconference for shareholders on Monday, March 25 at 10:00 a.m..
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that Mark Staples PhD has joined Nymox as Vice President for Chemistry, Manufacturing, and Controls (CMC). During his career Dr Staples has led innovative pharmaceutical development teams, supervised successful CMC modules of regulatory filings for drugs and biologics, managed technology transfer to production facilities, and functioned in upper management in a variety of senior positions. Dr Staples held senior positions with highly successful biopharmaceutical companies such as Biogen and other well-known corporations.
It is a pleasure to report that the Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is up 36% in the last quarter. But that can't change the reality that over the longer termRead More...
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC, as the Company's Director of Quality and EU Qualified Person, for all of Nymox's Chemistry, Manufacturing and Controls Operations. Dr Thomson is an authority in the field of Quality Assurance and Control in the Chemical and Pharmaceutical Industries. Dr. Thomson is a Fellow of the Royal Society of Chemistry (UK), a Chartered Chemist and Chairman of the Royal Society of Chemistry Qualified Persons Assessors Panel. He has worked in the pharmaceutical industry in positions including Head of Quality and Director of QA and Regulatory Affairs, and as Consultant Qualified Person at numerous large and small drug manufacturing facilities in the EU and the US for over 20 years. Dr. Thomson was a Chartered Scientist with The Science Council (UK) from 2004-2010 and Corporate Member of the South African Chemical Institute from 1980-1999.
Management will discuss the Company's current business progress with an update on its regulatory submission activities in the US and EU. To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.
If you own shares in Nymox Pharmaceutical Corporation (NASDAQ:NYMX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
HASBROUCK HEIGHTS, N.J., Jan. 15, 2019 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that a new peer review article has been published in Therapeutic.
HASBROUCK HEIGHTS, N.J., Dec. 19, 2018 -- Following the Nymox (NASDAQ: NYMX) Annual General Meeting yesterday (December 18, 2018), Nymox management discussed many significant.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
The St. Laurent, Quebec-based company said it had a loss of 5 cents per share. The biopharmaceutical company posted revenue of $40,000 in the period. In the final minutes of trading on Tuesday, the company's ...
On a per-share basis, the St. Laurent, Quebec-based company said it had a loss of 4 cents. The biopharmaceutical company posted revenue of $88,000 in the period. In the final minutes of trading on Monday, ...
In this article, I’m going to take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...